Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Work In Process: 2021-2025

Historic Work In Process for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Sep 2025 value amounting to $18.3 million.

  • Mirum Pharmaceuticals' Work In Process rose 28.38% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 28.38%. This contributed to the annual value of $16.1 million for FY2024, which is 62.96% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Work In Process of $18.3 million as of Q3 2025, which was up 12.23% from $16.3 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Work In Process' 5-year high stood at $18.3 million during Q3 2025, with a 5-year trough of $553,000 in Q1 2022.
  • For the 3-year period, Mirum Pharmaceuticals' Work In Process averaged around $12.5 million, with its median value being $11.6 million (2024).
  • Data for Mirum Pharmaceuticals' Work In Process shows a peak YoY surged of 1,072.51% (in 2023) over the last 5 years.
  • Mirum Pharmaceuticals' Work In Process (Quarterly) stood at $570,000 in 2021, then soared by 838.77% to $5.4 million in 2022, then skyrocketed by 84.51% to $9.9 million in 2023, then skyrocketed by 62.96% to $16.1 million in 2024, then rose by 28.38% to $18.3 million in 2025.
  • Its Work In Process was $18.3 million in Q3 2025, compared to $16.3 million in Q2 2025 and $15.8 million in Q1 2025.